TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00782951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Org 28611
Description: single IV dose of Org 28611 3 mcg/kg after dental impaction surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine sulfate
Description: single IV dose of morphine sulfate 0.12 mg/kg after dental impaction surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single IV dose of placebo after dental impaction surgery
Study: NCT01292642

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: individual CBT once weekly, 50 minutes, for 10 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy
Description: 1. 21 mg patch for 6 weeks, 14 mg patch for 2 weeks, then 7 mg patch for 2 weeks~2. 14 m g patch for 8 weeks, then 7 mg patch for 2 weeks
Study: NCT03138538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1: M8891
Description: Participants receives M8891 orally once daily at escalated dose levels under fasting condition for consecutive 21-day cycles of continuous treatment until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1: M8891
Description: Participants receives M8891 orally once daily at escalated dose levels under fasting condition for consecutive 21-day cycles of continuous treatment until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1: M8891
Description: Participants receives M8891 orally once daily at escalated dose levels under fasting condition for consecutive 21-day cycles of continuous treatment until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1: M8891
Description: Participants receives M8891 orally once daily at escalated dose levels under fasting condition for consecutive 21-day cycles of continuous treatment until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1: M8891
Description: Participants receives M8891 orally once daily at escalated dose levels under fasting condition for consecutive 21-day cycles of continuous treatment until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1: M8891
Description: Participants receives M8891 orally once daily at escalated dose levels under fasting condition for consecutive 21-day cycles of continuous treatment until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
Study: NCT05054972

Intervention type: PROCEDURE
Intervention: Exclusion of the aortic aneurysm.
Description: Surgical procedure in which an aortic aneurysm is excluded.

Intervention type: PROCEDURE
Intervention: Exclusion of the aortic aneurysm.
Description: Surgical procedure in which an aortic aneurysm is excluded.

Intervention type: PROCEDURE
Intervention: Exclusion of the aortic aneurysm.
Description: Surgical procedure in which an aortic aneurysm is excluded.

Intervention type: PROCEDURE
Intervention: Exclusion of the aortic aneurysm.
Description: Surgical procedure in which an aortic aneurysm is excluded.
Study: NCT01860924

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: vigorous intensity exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: health education
Description: education
Study: NCT01652885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2728 Topical Ointment, 2%
Description: AN2728 Topical Ointment, 2%
Study: NCT03189875

Intervention type: OTHER
Intervention: Standard of Care
Description: Participants will be followed as per local routine clinical practice
Study: NCT01395394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kuvan
Description: Participants in the BH4 Non-Responder group will be given a 20 mg/kg body weight/day dose of Kuvan to take on a daily basis for two weeks. The last dose will be administered at the participant's study visit 2.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal Challenge
Description: At each study visit, patients will receive a meal high in polyunsaturated fats that will promote a transitory increase in oxidative stress measures and endothelial dysfunction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal Challenge
Description: At each study visit, patients will receive a meal high in polyunsaturated fats that will promote a transitory increase in oxidative stress measures and endothelial dysfunction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal Challenge
Description: At each study visit, patients will receive a meal high in polyunsaturated fats that will promote a transitory increase in oxidative stress measures and endothelial dysfunction
Study: NCT00641251

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intensive medical management
Description: IMM will include rigorous lifestyle modification for weight loss and stepped pharmacologic treatment consistent with standard of care for diabetes and other CVD risk factors.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RYGB & IMM
Description: Roux-en-Y gastric bypass Surgery combined with intensive medical management
Study: NCT02658123

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pre-operative education (standard of care)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-operative education (standard of care)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home health care visits (standard of care)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home health care visits (standard of care)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up post-operative visits

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up post-operative visits

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Data Collection Form
Description: -Form that contains date, area to record number of pouches, and if home health care visit took place.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Data Collection Form
Description: -Form that contains date, area to record number of pouches, and if home health care visit took place.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthcare Utilization Form
Description: * Form for patient to record if they visited an emergency room or urgent care or if they were hospitalized~* Form allows patient to record reason for visit and date of visit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthcare Utilization Form
Description: * Form for patient to record if they visited an emergency room or urgent care or if they were hospitalized~* Form allows patient to record reason for visit and date of visit

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The City of Hope QOL Survey for Ostomy Patients
Description: * Consists of 47 questions asking various physical, psychological, sexual, work-related, and demographic questions.~* Additional 34 questions on how the ostomy affects quality of life. Answers range from 0=not at all to 10=severe problem.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The City of Hope QOL Survey for Ostomy Patients
Description: * Consists of 47 questions asking various physical, psychological, sexual, work-related, and demographic questions.~* Additional 34 questions on how the ostomy affects quality of life. Answers range from 0=not at all to 10=severe problem.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone call with CWOCN or PA
Study: NCT04106700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 MG
Description: Apixaban will be started simultaneously with anti myeloma treatment on day 1 of cycle 1 of VTD, and continues for 4 to 6 months depending on the number of induction cycles administered to the patient
Study: NCT00586261

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone 30 mg daily for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 30 mg daily for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitroglycerin
Description: 0.4 mg sublingual nitroglycerin tablet was given to all patients without a contraindication to check the brachial reactivity.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitroglycerin
Description: 0.4 mg sublingual nitroglycerin tablet was given to all patients without a contraindication to check the brachial reactivity.
Study: NCT04163809

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality with Oculus Go headset
Description: The investigator will place the Oculus Go VR headset on the patient. VR will provide distracting, pleasant visual stimulus from the beginning of the procedure (while the patient is being cleaned and draped) and removed immediately after the regional anesthesia procedure is complete for roughly 10-20 minutes. All patients receiving VR will view the same scene.
Study: NCT03011346

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Symetis ACURATE neo/TF transfemoral TAVI system
Description: Transcatheter aortic valve implantation of a Symetis ACURATE neo/TF bioprosthesis by transfemoral access, pre-dilatation mandatory.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Edwards Sapien 3 Transcatheter Heart Valve
Description: Transcatheter aortic valve implantation of an Edwards Sapien 3 bioprosthesis by transfemoral access.
Study: NCT02229071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib(200mg)
Description: Donafenib 200mg,bid,po

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donafenib(300mg)
Description: Donafenib 300mg,bid,po
Study: NCT01197326

Intervention type: DEVICE
Intervention: use of the MP5 EWS patient monitor
Description: All patients on the study ward receive the same care in Groups 1 and 2. The only difference is the device used to collect the vital signs. In Group 2, the MP5 EWS spot check monitor (FDA approved and CE marked) is the vital signs collection device.

Intervention type: DEVICE
Intervention: use of the MP5 EWS patient monitor
Description: All patients on the study ward receive the same care in Groups 1 and 2. The only difference is the device used to collect the vital signs. In Group 2, the MP5 EWS spot check monitor (FDA approved and CE marked) is the vital signs collection device.
Study: NCT04475055

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostisches Interview bei psychischen Störungen (DIPS)
Description: The DIPS is a structured interview which assesses the most frequent psychological disorders. It can be delivered by trained clinicians and takes between 50-120 minutes. Its acceptance with patients is very good.
Study: NCT00666458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saxagliptin
Description: tablet, per oral, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sitagliptin
Description: capsule, per oral, once daily
Study: NCT01465906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tulobuterol
Description: patch, 2mg, qN, 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium Bromide
Description: 18ug, inhale, qD, 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium bromide
Description: 18ug, inhale, qD, 3 months
Study: NCT00650910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: 1500 mg oral lapatinib starting Day 2 continuing through Day 9. Part 2 subjects received 1500mg daily through week 10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: 0.5mg on Days 1 and 9
Study: NCT00891605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: 150 mg of ABT-263 is taken orally once daily on Days 1-3 out of each 21 day cycle. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 175 mg/m2 over 3 hours of paclitaxel will be given by intravenous infusion on Day 1 of each 21 day cycle.~Note - The dose and schedule is subject to change based on the toxicities observed.
Study: NCT04320238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human interferon Alpha-1b
Description: recombinant human interferon Alpha-1b nasal drops, 2-3 drops for each nostril per time, 4 times per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human interferon Alpha-1b
Description: recombinant human interferon Alpha-1b nasal drops, 2-3 drops for each nostril per time, 4 times per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thymosin alpha 1
Description: thymosin alpha 1 subcutaneous injection 1 time per week.
Study: NCT02700490

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Behaviour Therapy or Cognitive Behaviour Therapy which forms service as usual in primary care centres in Indonesia.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy
Description: Behaviour Therapy or Cognitive Behaviour Therapy which forms service as usual in primary care centres in Indonesia.
Study: NCT01372904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Phosphate
Description: 0.7ml of Dexamethasone Phosphate 10mg/ml would be injected unilaterally to the middle ear using 25 gauge spinal needle.~The trans-tympanic membrane injection would take place at the posterior inferior quadrant of the ear drum facing the round window niche. The patient would be instructed to lie down for 20 minutes after the injection with the treated side up and to avoid swallowing or coughing. Intratympanic Dexamethasone would be delivered immediately prior to each cisplatin treatment as maximal level.
Study: NCT03637933

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic tattooing
Description: The tattoo has to be placed 1 or 2 cm distal to the lesion and tattooing has to be performed in at least 2 of the 4 quadrants of the bowel. A 0.5-1 mL saline bleb has to be raised submucosally and then a similar quantity of India Ink or Sterile Carbon Particle Suspension has to be injectiected into that bleb.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic tattooing
Description: The tattoo has to be placed 1 or 2 cm distal to the lesion and tattooing has to be performed in at least 2 of the 4 quadrants of the bowel. A 0.5-1 mL saline bleb has to be raised submucosally and then a similar quantity of India Ink or Sterile Carbon Particle Suspension has to be injectiected into that bleb.
Study: NCT03378076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX006 32 mg
Description: Drug: Extended-release 32 mg FX006 IA injection into each knee (total 64 mg dose)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAcs 40 mg
Description: Drug: Immediate-release 40mg TAcs IA injection into each knee (total 80 mg dose)
Study: NCT03718507

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: atropine (0.01-0.02 mg/kg i.v. bolus) and fentanyl (0.5-2 mcg/kg i.v. in 5 minutes)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sucrose 24% Oral Solution
Description: 0.5 ml given orally 2 minutes before LISA procedure
Study: NCT00489567

Intervention type: PROCEDURE
Intervention: Blood sample collection
Study: NCT04190225

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital/social media intervention
Description: Participants will receive individual counseling, access to an individually tailored website, guided goal setting via texts, access to a study Instagram account, and a wearable tracker (Fitbit)
Study: NCT03628014

Intervention type: OTHER
Group type: OTHER
Intervention: Inpatient-care program
Description: Patients enrolled in the Hospital Elder Life Program can receive four types of personalized volunteer-led interventions based on the needs identified by the care team. These interventions include:~* Daily orientation and visiting program~* Basic active movements~* Meal assistance~* Recreational activities
Study: NCT01240161

Intervention type: DRUG
Intervention: FLT-PET/CT: (3'deoxy-3'-[(18)F] fluorothymidine) PET/CT
Description: Each patient will have 0-3 or more FLT-PET brain scans.
Study: NCT02242955

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diazepam
Description: 40 mg per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam
Description: 40 mg per day.
Study: NCT03986489

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based dance/movement therapy (M-DMT)
Description: M-DMT includes benefits of physical activity, group psychotherapy, mindfulness training, and an art-based intervention in a unified practice. Each online session focuses on different psycho-educational topics about chronic low back pain management and links these topics with specific M-DMT activities that incorporate mindfulness-based principles and techniques.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Chronic pain social support group
Description: The therapist will facilitate online open group discussions about participants' experiences with or reactions to the topic of discussion and will promote empathy among group members. The therapist will use client-centered, reflective listening techniques but will not prescribe any specific recommendations for change.~Each week, SSG participants will receive emails with brief information about the topic discussed during the group session.
Study: NCT00084123

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healing Touch Therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Therapy

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard Care
Description: Standard Care
Study: NCT04667351

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2400 mg/m² 5-fu
Description: Hepatic arterial infusion of oxaliplatin,leucovorin and 2400 mg/m² 5-FU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1200 mg/m² 5-fu
Description: Hepatic arterial infusion of oxaliplatin,leucovorin and 1200 mg/m² 5-FU
Study: NCT02103569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC of Daclatasvir, Asunaprevir and BMS-791325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC of Norethindrone and Ethinyl Estradiol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-791325
Study: NCT02872766

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CXL Myopia
Description: Applying riboflavin 0,22% to 0,25 % up to 20 minutes . Then, the eyes are exposed to UVA light with the KXL II system according to the programmed treatment pattern.
Study: NCT04578795

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single use flexible ureteroscopy (PUSEN-OLIMPUS)
Description: single use flexible ureteroscopy
Study: NCT03289650

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: immunosuppressive agent tacrolimus, given twice-daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus Extended Release Oral Tablet [Envarsus]
Description: immunosuppressive agent extended-release tacrolimus, given once daily
Study: NCT03325673

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TrueTear
Description: TrueTear Device (Intranasal Tear Neurostimulator) was used intranasally on CL wear days; it was also used on non-CL wear days if the participant chose. The number of applications was determined by participant.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TrueTear Sham Control
Description: TrueTear sham device, which is not electrically active and has limited tip insertion depth, was used intranasally on CL wear days; it was also used on non-CL wear days if participant chose. The number of applications was determined by participant.
Study: NCT05448872

Intervention type: DRUG
Intervention: Sacubitril/Valsartan
Description: HF patients treated with Sac/Val
Study: NCT04479163

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma
Description: 250 ml Convalescent plasma with an IgG titer against SARS CoV2

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline 0.9%
Study: NCT00748579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-1827452
Description: I.V. infusion for 0.5 hour at 54mg/hr followed by 1 hour at 21mg/hr

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-1827452
Description: I.V. infusion for ≤ 1 hour at 72mg/hr followed by 1 hour at 36mg/hr
Study: NCT02025426

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine
Study: NCT00789529

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Opti-Free® RepleniSH® MPDS
Description: soft contact lens disinfecting solution

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReNu MultiPlus®
Description: soft contact lens disinfecting solution
Study: NCT03695003

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cognivia
Description: Cognivia is a trademarked sage/polyphenol combination dietary supplement from Nexira

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control capsules were prepared by Nexira also and are aesthetically identical to the Cognivia capsules
Study: NCT01262365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epratuzumab
Description: 600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12- week treatment cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epratuzumab
Description: 1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo infusions delivered weekly for 4 weeks over four 12-week treatment cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusions delivered weekly for 4 weeks over four 12-week treatment cycles
Study: NCT01817309

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: endotoxin assay in peritoneal dialysis effluent
Description: endotoxin level by Limulus Amebocyte Lysate (LAL) assay
Study: NCT00820898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV